Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Peng Liu, Hang Su et al.|The Lancet Haematology|2019Cited by 248
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Jun Zhu, Yao Liu et al.|The Lancet Oncology|2023Cited by 55
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimabYuankai Shi, Bo Peng, Hang Su et al.|EBioMedicine|2020Cited by 41
Automatic Recognition of Oil Industry Facilities Based on Deep LearningNannan Zhang, Yang Liu, Liqun Zou et al.|Unknown|2018Cited by 16
PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphomaYiqin Wang, Ming Jiang, Li Xie et al.|Journal of Cancer Research and Clinical Oncology|2019Cited by 14